MedTrace Logo

High Frequency Stimulation to Improve Cognition, Mobility, and Affect in Individuals With Subjective Cognitive Decline

NCT07395609 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-14

No results posted yet for this study

Summary

The goal is to determine whether three months of at least three times / week of sensory flicker stimulation improves cognition, mobility, and affect in healthy older adults and older adults with Subjective Cognitive Decline (SCD), relative to an SCD control group. Investigators will also determine whether the intervention slows cortical thinning and declines in brain functional network segregation and changes in blood biomarkers of Alzheimer's Disease (AD).

Conditions

  • Subjective Cognitive Decline (SCD)
  • Healthy Subjects

Interventions

BEHAVIORAL

Flicker Stimulation

Investigators will combine ultrasound (≥22 kHz) and near-infrared two-photon stimulation (890-940 nm) to deliver rhythmic input in a subliminal, comfortable manner, without the side effects associated with visible flicker.

BEHAVIORAL

Control Stimulation

The control group will receive a control stimulation rather than a constant flicker frequency.

BEHAVIORAL

40 Hz Visual Occlusion

Participant will wear visual occlusion glasses with visible stimulation flickering at 40 Hz

BEHAVIORAL

Control - Visual Occlusion

Participants will receive visible stimulation at a frequency that is not 40 Hz.

Sponsors & Collaborators

  • University of Florida

    lead OTHER

Principal Investigators

  • Rachael Seidler · University of Florida

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-15
Primary Completion
2028-10-31
Completion
2028-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07395609 on ClinicalTrials.gov